Terms: = Leukemia AND PR, PGR, progesterone receptor AND Treatment
760 results:
1. [The Efficacy and Safety of Venetoclax Combined with Azacitidine in the treatment of Adult Patients with Acute Myeloid leukemia Who Are Unfit for Intensive Chemotherapy].
Wang KY; Fan BR; Zhang QW; Han MR; Ge XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):342-346. PubMed ID: 38660834
[TBL] [Abstract] [Full Text] [Related]
2. Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation treatment for adolescent and adult Tlymphoblastic leukemia /lymphoma: a large cohort multicenter study in China.
Luo L; Jiao Y; Li Y; Yang P; Gao J; Huang S; Huang W; Wang J; Dong F; Ke X; Zou D; Gao C; Jing H
Ann Hematol; 2024 Jun; 103(6):2073-2087. PubMed ID: 38581546
[TBL] [Abstract] [Full Text] [Related]
3. Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study.
Chiappella A; Casadei B; Chiusolo P; Di Rocco A; Ljevar S; Magni M; Angelillo P; Barbui AM; Cutini I; Dodero A; Bonifazi F; Tisi MC; Bramanti S; Musso M; Farina M; Martino M; Novo M; Grillo G; Patriarca F; Zacchi G; Krampera M; Pennisi M; Galli E; Martelli M; Ferreri AJM; Ferrari S; Saccardi R; Bermema A; Guidetti A; Miceli R; Zinzani PL; Corradini P
Leukemia; 2024 May; 38(5):1107-1114. PubMed ID: 38459167
[TBL] [Abstract] [Full Text] [Related]
4. Efficacy and safety of azacitidine in pediatric patients with newly diagnosed advanced myelodysplastic syndromes before hematopoietic stem cell transplantation in the AZA-JMML-001 trial.
Locatelli F; Strålin KB; Schmid I; Sevilla J; Smith OP; van den Heuvel-Eibrink MM; Zecca M; Zwaan CM; Gaudy A; Patturajan M; Poon J; Simcock M; Niemeyer CM
Pediatr Blood Cancer; 2024 May; 71(5):e30931. PubMed ID: 38433307
[TBL] [Abstract] [Full Text] [Related]
5. [Venetoclax Combined with CACAG Regimen in the treatment of Patients with Refractory/Relapse Acute Myeloid leukemia: A Prospective Clinical Study].
Gao WJ; Yang JJ; Li M; Wen YN; Jiao YF; LE N; Liu YC; Wang N; Huang S; Dou LP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):90-95. PubMed ID: 38387905
[TBL] [Abstract] [Full Text] [Related]
6. [Immune Reconstitution after BTKi treatment in Chronic Lymphocytic leukemia].
Wang YL; Tang PX; Chen KL; Guo GY; Long JL; Zou YQ; Liang HY; Xu ZS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):1-5. PubMed ID: 38387891
[TBL] [Abstract] [Full Text] [Related]
7. Clinical features and prognosis of chronic natural killer cell lymphoproliferative disorders.
Liu DL; Wang YJ; Qian SY; Ma SS; Ding MJ; Dong M; Zhang JM; Zhang MZ; Chen QJ; Zhang XD
Hematology; 2024 Dec; 29(1):2307817. PubMed ID: 38319083
[TBL] [Abstract] [Full Text] [Related]
8. [Analysis of efficacy and safety of daratumumab-containing regimen in relapsed and refractory multiple myeloma patients].
Yu QR; Zhou X; Wu HY; Hao LM; Li XM; Zhong YP
Zhonghua Yi Xue Za Zhi; 2024 Feb; 104(7):521-525. PubMed ID: 38317364
[No Abstract] [Full Text] [Related]
9. Nelarabine-containing salvage therapy and conditioning regimen in transplants for pediatric T-cell acute lymphoblastic leukemia and lymphoma.
Yanagi M; Mori M; Honda M; Mitani Y; Seki M; Fukuoka K; Oshima K; Arakawa Y; Koh K
Int J Hematol; 2024 Mar; 119(3):327-333. PubMed ID: 38302839
[TBL] [Abstract] [Full Text] [Related]
10. Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia.
Stilgenbauer S; Tausch E; Roberts AW; Davids MS; Eichhorst B; Hallek M; Hillmen P; Schneider C; Schetelig J; Böttcher S; Kater AP; Jiang Y; Boyer M; Popovic R; Ghanim MT; Moran M; Sinai WJ; Wang X; Mukherjee N; Chyla B; Wierda WG; Seymour JF
Blood Adv; 2024 Apr; 8(8):1992-2004. PubMed ID: 38290108
[TBL] [Abstract] [Full Text] [Related]
11. Combination of minimal residual disease on day 15 and copy number alterations results in BCR-ABL1-negative pediatric B-ALL: A powerful tool for prediction of induction failure.
Baghdadi H; Soleimani M; Zavvar M; Bahoush G; Poopak B
Cancer Genet; 2024 Apr; 282-283():27-34. PubMed ID: 38183785
[TBL] [Abstract] [Full Text] [Related]
12. [Novel CD19-KIRS2/Dap12-BB CAR-T treatment for 3 Patients with Relapsed and Refractory B-Cell Tumors].
Ji SW; Hua T; Wang JJ; Shao LY; Chen ZH; Liu JY; Cheng H; Chen W; Sun C; Wang X; Xu KL; Cao J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1860-1865. PubMed ID: 38071073
[TBL] [Abstract] [Full Text] [Related]
13. [Safety and the Short-Term Efficacy of Venetoclax Combined with Azacitidine Followed by Cladribine in Children with Refractory/Relapsed Acute Myeloid leukemia].
DU WW; Liu SX; Wang Y; He HL; Guo AL; Hu SY; Lu J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1635-1638. PubMed ID: 38071039
[TBL] [Abstract] [Full Text] [Related]
14. Venetoclax combined with hypomethylating agents and the CAG regimen in relapsed/refractory AML: a single-center clinical trial.
Liu Y; Li Y; Zhang R; Yu Z; Jing Y
Front Immunol; 2023; 14():1269163. PubMed ID: 38054008
[TBL] [Abstract] [Full Text] [Related]
15. Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies.
Carneiro BA; Cavalcante L; Mahalingam D; Saeed A; Safran H; Ma WW; Coveler AL; Powell S; Bastos B; Davis E; Sahai V; Mikrut W; Longstreth J; Smith S; Weisskittel T; Li H; Borden BA; Harvey RD; Sahebjam S; Cervantes A; Koukol A; Mazar AP; Steeghs N; Kurzrock R; Giles FJ; Munster P
Clin Cancer Res; 2024 Feb; 30(3):522-531. PubMed ID: 37982822
[TBL] [Abstract] [Full Text] [Related]
16. [Chemotherapy Combined with Venetoclax Followed by Allo-Hematopoietic Stem Cell Transplantation for treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm].
Cheng P; Wang LL; Wang QX; Guan J; Zhou Y; Hu B; Feng Y; Zou L; Cheng H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1531-1536. PubMed ID: 37846712
[TBL] [Abstract] [Full Text] [Related]
17. [Efficacy of Venetoclax Plus Azacitidine in Relapsed/Refractory Acute Myeloid leukemia Patients with
Weng GY; You WW; Liu HX; Cai Y; DU X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1333-1339. PubMed ID: 37846681
[TBL] [Abstract] [Full Text] [Related]
18. Effect of asciminib and vitamin K2 on Abelson tyrosine-kinase-inhibitor-resistant chronic myelogenous leukemia cells.
Okabe S; Gotoh A
BMC Cancer; 2023 Sep; 23(1):827. PubMed ID: 37670241
[TBL] [Abstract] [Full Text] [Related]
19. [Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation treatment for T lymphoblastic leukemia/lymphoma].
Luo L; Jiao Y; Yang P; Li Y; Huang WY; Ke XY; Zou DH; Jing HM
Zhonghua Xue Ye Xue Za Zhi; 2023 May; 44(5):388-394. PubMed ID: 37550188
[No Abstract] [Full Text] [Related]
20. In-vivo and human evidence for potential efficacy of therapeutic polyclonal RSV neutralizing antibodies for palivizumab-resistant RSV infections.
Ramirez KA; Mond J; Papenburg J; Boivin G; Gilbert BE; Falsey AR; Bagga B; DeVincenzo JP
Virology; 2023 Sep; 586():115-121. PubMed ID: 37542818
[TBL] [Abstract] [Full Text] [Related]
[Next]